Xiwi Microorganism Completes Nearly 100 Million Yuan Series A Funding Round Led by Dalton Venture, Building an Innovative Ophthalmic Biology and Polymer Materials Platform | Dalton Venture News
Recently, **Xiwei (Suzhou) Biomedical Technology Co., Ltd.** (hereinafter referred to as "Xiwei Biotech") **announced the completion of a nearly RMB 100 million Series A funding round, led by Dalton Venture**. The proceeds will be used to accelerate the development of its pipeline of ophthalmic and regenerative medicine innovations — including artificial biomimetic corneas, implantable contact lenses, artificial corneal endothelium sheets, and artificial dermis — as well as clinical trials, international regulatory registration, and marketing expansion.
Dalton News
Recently, Xiwei (Suzhou) Biomedical Technology Co., Ltd. (hereinafter referred to as "Xiwei Biotech") announced the completion of a nearly RMB 100 million Series A funding round, led by Dalton Venture. The proceeds will accelerate the R&D of its pipeline of innovative ophthalmic and regenerative medicine products — including artificial biomimetic corneas, implantable contact lenses, artificial corneal endothelium grafts, and artificial dermis — as well as clinical trials, international regulatory registration, and commercial expansion.
Founded in 2020, Xiwei Biotech specializes in developing innovative ophthalmic implantable medical devices and regenerative medicine devices based on novel biomodified materials. The company's core founding team brings over 15 years of R&D and management experience in the international and domestic pharmaceutical sectors. It operates approximately 5,600 square meters of R&D and production facilities, including three static ISO Class 7 cleanrooms (with local static ISO Class 5 zones), and has established a comprehensive quality management system compliant with ISO 13485, FDA QSR 820, and China's Good Manufacturing Practice for Medical Devices.
In China, corneal disease is the third leading cause of blindness, affecting approximately 4 million people with corneal blindness — nearly half of whom could regain sight through corneal transplantation. The patient pool grows by 70,000 to 100,000 annually. Yet fewer than 10,000 corneal transplants are performed each year, and existing solutions carry drawbacks including aqueous humor leakage, glaucoma, and dissolution or detachment caused by rejection. Clinical demand for corneal transplantation and corneal endothelium products thus remains dramatically unmet, representing a massive and non-discretionary market. Meanwhile, China has roughly 600 million people with myopia, and femtosecond refractive surgeries currently number about 2.2 million per year. Implantable Collamer Lenses (ICLs) are gaining increasing favor among doctors and patients due to advantages such as no corneal tissue removal, simpler surgical and postoperative procedures, and reversibility.
Targeting these clinical pain points and vast market opportunities, Xiwei Biotech has developed a portfolio of innovative medical devices spanning artificial biomimetic corneas, implantable contact lenses, artificial corneal endothelium membranes, and artificial dermis. Building on globally leading and validated industry patents, the company has developed a key technology for crosslinking and copolymerizing polymer materials with synthetic self-assembling triple-helix structural biomimetic collagen materials, yielding products with significant advantages including enhanced biocompatibility, reduced protein adhesion, decreased calcification deposition, and controllable physicochemical properties.
Currently, the artificial biomimetic cornea for lamellar transplantation has entered clinical trials. The technology effectively resolves transparency and biocompatibility challenges in implanted products, with patients showing no postoperative rejection, minimal inflammatory response, and no need for lifelong immunosuppressive or steroid medications. The company's other core product, implantable contact lenses, is now in animal evaluation; testing indicates that its optical parameters and safety profile are comparable to internationally marketed leading products. Additionally, the use of synthetic collagen-mimetic peptides may overcome the religious limitations associated with animal-derived collagen in existing marketed products, laying groundwork for the company's international market expansion.
Xiwei Biotech is committed to restoring sight to millions of blind patients and improving visual quality for tens of millions of people with myopia. It researches biomimetic fusion materials that transcend the boundaries of biomass, polymers, and small-molecule substances, developing world-leading medical devices to meet human needs in optics, biological scaffolding, and regenerative repair.
On this funding round, Xiwei Biotech's founder stated: The successful completion of this financing will strongly accelerate our existing product development. With the joint efforts of all employees and shareholders, we will bring our products to market as soon as possible, alleviate patient suffering, and advance China's ophthalmic medical devices to the international forefront. All employees remain steadfast in our belief that Xiwei represents a ray of morning light guarding human health, bringing brightness and hope to patients!
Dalton Venture commented: The company possesses leading technological patents, with products applicable to multiple implant scenarios requiring biocompatibility and optical performance. It has assembled an experienced team spanning R&D, manufacturing, regulatory affairs, and quality management, demonstrating the potential to grow into a platform-type enterprise. We very much look forward to working alongside Xiwei to drive innovative products to market and bring the benefits of clear, bright vision to numerous patients.
ID: daltonventure
Long press to follow
Recommended Reading
